What is the generic version of colchicine?

Mitigare® (colchicine) 0.6 mg Capsules, and its authorized generic, colchicine 0.6 mg capsules, are a distinctive two-tone blue color.

Is colchicine brand name or generic?

Colchicine oral tablet is available as both a generic and brand-name drug. Brand name Colcrys. It also comes in capsules that are also available as both a generic and brand-name drug. Brand name: Mitigare.

What is a substitute for colchicine?

ColciGel® is a first line agent in the treatment of acute gout flares and an alternative to oral colchicine in those patients who experience either adverse drug effects (ADRs) or who do not achieve suitable symptom relief.

Is colchicine and allopurinol the same?

Zyloprim (allopurinol) works well to prevent gout attacks and is cheaper than some alternatives, but it takes a few weeks to start working. Prevents and treats gout. Colcrys (colchicine) is a second-choice treatment for gout attacks. Be careful how much you use since it can cause problems with your blood.

When did generic colchicine come out?

In September 2014, the FDA granted approval for Hikma to market and sell Mitigare, a colchicine capsule for the prophylactic treatment of gout.

What is the new medication for gout?

The U.S. Food and Drug Administration today approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

Is indomethacin 50 mg a narcotic?

If you experience any mental health changes, including anxiety, while taking this medication, contact your provider. Is indomethacin (Indocin) a controlled substance? No, indomethacin (Indocin) is not a controlled substance.

What’s another name for indomethacin?


Clinical data
Trade names Indocid, Indocin
Other names Indomethacin (USAN US )
AHFS/Drugs.com Monograph
License data US FDA: Indomethacin

Why is generic colchicine so expensive?

“Public spending on colchicine has grown exponentially, mainly from ongoing price increases after Colcrys’s approval and market exclusivity, potentially limiting millions of U.S. patients from affording its benefits as a long-term therapy for gout or after myocardial infarction,” McCormick and colleagues wrote.